DYRK2 is a novel therapeutic target in ER negative breast cancer

被引：0
|
作者：
Edwards, J.
Baillie, G.
Quinn, J.
Monreno, R.
Banerjee, S.
Tomkinson, N.
MacKay, S.
De La Vega, L.
机构：
[1] Univ Glasgow, Glasgow, Lanark, Scotland
[2] Univ Dundee, Dundee, Scotland
[3] Univ Calif San Diego, La Jolla, CA 92093 USA
[4] Univ Strathclyde, Glasgow, Lanark, Scotland
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P3-10-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-10-10
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Emerging roles of DYRK2 in cancer
    Tandon V.
    De La Vega L.
    Banerjee S.
    Journal of Biological Chemistry, 2021, 296
  • [2] Emerging roles of DYRK2 in cancer
    Tandon, Vasudha
    de la Vega, Laureano
    Banerjee, Sourav
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2021, 296
  • [3] Transcription factor NFIB represents a potential novel therapeutic target for ER-negative breast cancer
    Andre, F.
    Wang, B.
    Hartzis, C.
    Mazouni, C.
    Wang, J.
    Sotiriou, C.
    Symmans, W. F.
    Pusztai, L.
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2007, 22 (01): : 60 - 60
  • [4] Biological functions of ERβ in triple negative breast cancer and its utility as a novel therapeutic drug target
    Reese, J. M.
    Bruinsma, E. S.
    Suman, V. J.
    Nelson, A. W.
    Chernukhin, I.
    Carroll, J. S.
    Ingle, J. N.
    Goetz, M. P.
    Hawse, J. R.
    CANCER RESEARCH, 2017, 77
  • [5] Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer
    Enomoto, Yasuko
    Yamashita, Shin-ichi
    Yoshinaga, Yasuteru
    Fukami, Yasuyoshi
    Miyahara, So
    Nabeshima, Kazuki
    Iwasaki, Akinori
    TUMOR BIOLOGY, 2014, 35 (11) : 11021 - 11025
  • [6] Multiple functions of DYRK2 in cancer and tissue development
    Yoshida, Saishu
    Yoshida, Kiyotsugu
    FEBS LETTERS, 2019, 593 (21) : 2953 - 2965
  • [7] DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail
    Mimoto, Rei
    Taira, Naoe
    Takahashi, Hiroyuki
    Yamaguchi, Tomoko
    Okabe, Masataka
    Uchida, Ken
    Miki, Yoshio
    Yoshida, Kiyotsugu
    CANCER LETTERS, 2013, 339 (02) : 214 - 225
  • [8] Evaluation of GABRP as a novel therapeutic target in triple negative breast cancer
    Wali, Vikram B.
    Patwardhan, Gauri A.
    Hatzis, Christos
    Pusztai, Lajos
    CANCER RESEARCH, 2017, 77
  • [9] ER-α36: a novel biomarker and potential therapeutic target in breast cancer
    Su, Xingyun
    Xu, Xin
    Li, Guangliang
    Lin, Bingyi
    Cao, Jiang
    Teng, Lisong
    ONCOTARGETS AND THERAPY, 2014, 7 : 1525 - 1533
  • [10] Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer
    Shao, Claire
    Anand, Vivek
    Andreeff, Michael
    Battula, Venkata Lokesh
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2022, 1508 (01) : 35 - 53
12345